Free press releases distribution network?

Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University - At the 2008 International Conference for Alzheimer’s Disease, the VU University Medical Centre and Lund University presented a joint poster entitled, “Aβ1-42 binding and uptake by primary human astrocytes in vitro: Effects of a1-Antichymotrypsin”
AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University

 

PRZOOM - /newswire/ - San Jose, CA, United States, 2008/08/29 - At the 2008 International Conference for Alzheimer’s Disease, the VU University Medical Centre and Lund University presented a joint poster entitled, “Aβ1-42 binding and uptake by primary human astrocytes in vitro: Effects of a1-Antichymotrypsin”.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The authors of the study were H. M Nielsen, S. Janciauskiene, B. Holmqvist, and R. Veerhuis. The Aβ1-42 peptides that were a key ingredient in the research were supplied by AnaSpec, Inc.

The background of the research presentation noted that imbalance between the production and clearance of the amyloid β-peptide (Aβ) is a key event in the Alzheimer’s disease (AD) pathogenesis. Alpha1-antichymotrypsin (ACT) might influence the Aβ fibrillogenesis biological effects and clearance leading to enhanced Aβ deposition in the brain. Activated astrocytes are found surrounding amyloid plaques in AD brains but their role in AD pathogenesis is still poorly understood. These reactive cells over-express ACT and are able to release pro-inflammatory mediators. Recent evidence also suggests that rodent astrocytes may internalize and degrade extracellular Aβ. If also human primary astrocytes are capable of degrading Aβ 1-42, is still to be determined.

The authors presented the following conclusions:
· Primary human astrocytes are, during cytotoxic conditions, able to bind and take up Aβ1-42 in vitro, without a pro-inflammatory response.
· Human adult astrocytes derived from non-AD and AD subjects become Aβ1-42 positive upon exposure, in a similar manner, whereas a greater percentage of human fetal astrocytes become Aβ1-42 positive upon 1 mM and 10 mM o/n treatment with Aβ1-42.
· ACT has no or little effect on Aβ1-42 uptake by adult astrocytes whereas the uptake by fetal cells might be enhanced.
· Enhanced MCP-1 release upon Aβ/ACT co-treatment versus Aβ alone in adult astrocytes, might be mediated by ACT itself.

About VU University Medical Centre
The VU university medical centre has defined a number of clusters of research interest and patient care. The research themes primarily emcompass multi-and interdisciplinary research projects which include the entire spectrum of basic, strategic and applied research and are related to intramural, transmural and extramural medicine.

About Lund University
Founded in 1666 Lund University is an international centre for research and education that has approximately 38 000 students. It is respected as one of the best universities in Sweden. Internationally renowned research is carried out in several cutting-edge research fields, including nanotechnology and stem cell biology.

About AnaSpec
AnaSpec, Inc. is a leading provider of integrated proteomics solutions™ for worldwide life science research. With a vision for innovation through synergy, AnaSpec offers expertise in three primary technologies: peptides, detection reagents, and combinatorial chemistry.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Peptides Used in Latest Alzheimer’s Research by VU University Medical Centre and Lund University

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ping Yang 
408-452-5055 ping[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Soft Tissue Sarcoma Treatment Market Revenue Predicted To Go Up by 2025 Finds Persistence Market Research
Persistence Market Research Publishes Biopharmaceutical Membrane Filtration Market Forecast Over 2017-2025
Global Tablet Processing & Packaging Equipment Market to Reach USD 5,268.8 Million by 2022
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  MagLar, Inc.

Visit  BizJobs.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today